Peptide Knowledge Center
Liraglutide application (2)
Liraglutide, an analog of human hyperinsulinemic-like peptide-1 (GLP-1), stimulates insulin secretion in a glucose-concentration-dependent manner, while reducing excess glucagon levels in a glucose-concentration-dependent manner. secretion, delay gastric emptying, and reduce food intake through central appetite control; liraglutide can also enhance the sensitivity of peripheral tissues to insulin, thereby reducing postprandial blood glucose and body weight, therefore, clinically, liraglutide Peptides can be used alone or in combination with other oral hypoglycemic agents to control body weight or treat type 2 diabetes. A randomized controlled trial reported in the New England Journal showed that liraglutide may play a role in dyslipidemia and hypertension in obesity and overweight. Significant weight loss and improved metabolism in patients, while liraglutide can improve glycemic control, fasting insulin concentration, cardiometabolic markers and improve quality of life.
Because of its dual benefits of weight control and blood sugar control, the use of liraglutide is a unique treatment for obese individuals as well as those with type 2 diabetes. To investigate and investigate the efficacy and safety of liraglutide versus placebo for weight management in adults with overweight or obesity and type 2 diabetes, Davies et al conducted a 56-week trial at 126 sites in 9 countries. The results showed that the 3.0 mg/day subcutaneous injection of liraglutide group lost the most weight, and the weight loss in the 3.0 mg, 1.8 mg, and 1.2 mg groups decreased in turn, which proves that the weight loss effect of liraglutide increases with the dose, and the weight loss increases. many.
Liraglutide and dyslipidemia
To assess the effects of liraglutide and appropriate caloric reduction in overweight or obese prediabetic individuals, Ariel D et al. looked for obese or overweight prediabetic volunteers and randomly assigned age-matched, BMI-similar individuals to For two groups, a 14-week experiment was conducted. The liraglutide group lost 6.9 kg and the placebo group lost 3.3 kg. The metabolic indicators such as blood lipids and pre-lipoprotein generation in the liraglutide treatment group were more effective than those in the placebo group. Well, including reductions in cholesterol concentrations, LDL and triglycerides, LDL particles, etc., but little difference in lipoprotein handling. Liraglutide treatment group reduced fasting blood glucose in overweight or obese prediabetic populations, which can reduce a variety of lipids that have adverse effects on cardiovascular and cerebrovascular diseases, suggesting that this study deserves long-term further research